Skip to main content
FinSpry Logo
FinSpry
EDIT logo
EDIT
(NASDAQ)
Editas Medicine, Inc.
$2.67-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

Editas Medicine, Inc. (EDIT) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for Editas Medicine, Inc. stock.

Analyst Consensus Rating

Investment consensus from 5 professional research analysts

Consensus Rating

Strong Buy
Based on 5 unique analysts
Medium Confidence3.0:1 Buy/Sell

Average Price Target

$5.17
↑ 93.63% Upside

Loading chart...

Strong Sell
Sell
Hold
Buy
Strong Buy

Latest EDIT Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Soumit Roy
Jones Trading
Strong BuyUpgrades
$8.00
Geulah Livshits
Chardan Capital
Strong BuyMaintains
$3.50 → $3.50
Phil Nadeau
TD Cowen
BuyMaintains
-
Luca Issi
RBC Capital
HoldMaintains
$4.00
Alec Stranahan
BofA Securities
SellMaintains
-

Frequently Asked Questions

What is the analyst consensus rating for EDIT?

The analyst consensus rating for EDIT is "Strong Buy" based on 5 analyst recommendations.

What is the average price target for EDIT?

The average 12-month price target for EDIT is $5.17, representing an upside of 93.6% from the current price of $2.67.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.